Central regions | Technology & innovation

Solution to treat advanced-stage cancers under way in Russia

6 Apr '17
TheraMAB, a Russian biotech company, is conducting clinical trials for its drug candidate, designated TAB08, to treat cancers at advanced stages.

The new phase is expected to reveal the human bodys tolerance to the drug candidate and help assess possible immune response in an oncology patient.

The drug candidate is believed to be unique for its ability to address the very root of an oncologic disease by normalizing the functional balance between various types of immune cellsa drastic departure from conventional approach, in which drugs only deal with symptoms at later stages. The TAB08 drug candidate belongs to the IgG4 class of humanized monoclonal antibodies capable of binding the co-stimulating CB28 receptor specific for human T cells.

The candidate is reported to have already passed the initial clinical trial stage with success and proven its safety and good tolerance in healthy volunteers and autoimmune patients.

We believe therapy using stimulating drugs in combination with molecules that can trigger or suppress the immune system will benefit future cancer patients to a great extent, TheraMAB CEO Dmitry Tyrsin said.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
Find Related Content


Latest News: Central regions
24 Apr '17 | Materials, extraction | Technology & innovation
19 Apr '17 | Finance, business | Technology & innovation
18 Apr '17 | Technology & innovation
12 Apr '17 | Technology & innovation
12 Apr '17 | Technology & innovation

Feature stories

21 Apr '17
6 Mar '17
Developing a photonic computer, a technology that...
25 Jan '17
ScreenCardio-NN, an innovative company based in...
Search (News archive - 21071)
Why Russians do not smile
Nano & Giga Symposium

Latest News

24 Apr '17
Scientists at MISiS in Moscow have developed a fast...
21 Apr '17
A material almost identical to the human skin has...
20 Apr '17
In Tomsk, in Siberia, scientists are working on a new...

Most read stories from last week

24 Apr '17
Scientists at MISiS in Moscow have developed a fast...